Session: 330. Vascular Biology, Thrombosis, and Thrombotic Microangiopathies: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Fundamental Science, Research
To obtain mechanistic insights, we assessed the dynamics of cytokines in the tumor microenvironment (TME) and circulation, and the signaling pathways responsible for cytokine-induced TF upregulation in cancer cells and extracellular vesicles (EV). Cytokine expression in tumor and plasma from mice treated with IgG and ICI (anti-PD-1+anti-CTLA-4) was assessed using a cytokine array (proteome profiler) with densitometric analysis and also quantified with a Meso Scale Discovery (MSD) U-PLEX assay. Spearman's correlation analysis assessed cytokine correlations between tumor and plasma. T cell involvement was evaluated by depleting T cells with anti-CD4 and anti-CD8 antibodies before ICI treatment. IFN-γ effects on TF expression and TF+EV release by CT26 cancer cells were analyzed using pharmacological inhibition (JAK1/2 inhibitor) and genetic silencing (siRNA targeting IRF-1 and Rab27a).
Cytokine profiling in ICI-treated mice tumors showed significant increases in IFN-γ (2-fold) and its responsive chemokines, monokine induced by IFN-γ (MIG, 1.8-fold) and interferon-inducible T cell alpha chemoattractant (I-TAC, 8.8-fold), implying T cell recruitment. Elevated tumor necrosis factor (TNF-α, 6.8-fold) and B lymphocyte chemoattractant (BLC, 2.9-fold) were also observed, along with macrophage inflammatory protein-1beta (MIP-1β, 5.4-fold) and regulated on activation, normal T cell expressed and secreted (RANTES, 3.4-fold). Increased plasma keratinocyte-derived chemokine (KC, 4.7-fold), stromal cell-derived factor-1 (SDF-1, 2-fold), and monocyte chemotactic protein-5 (MCP-5, 3.4-fold) indicated myeloid cell activation. The U-PLEX multiplex assay confirmed significant increases in eight tumor cytokines from ICI-treated mice: IFN-γ (3.8-fold), TNF-α (1.6-fold), BLC (2.8-fold), MIP-1β (1.8-fold), RANTES (2.1-fold), SDF-1 (1.9-fold), IL-6 (1.7-fold), and GM-CSF (1.9-fold). The higher sensitivity of MSD platform detected increased circulating levels of IFN-γ (2.6-fold, 1.62 vs 0.63 pg/ml), TNF-α (1.6-fold, 11.98 vs 8.16 pg/ml), IL-6 (1.6-fold, 352.02 vs 218.88 pg/ml), MCP-5 (1.5-fold, 413.03 vs 276.45 pg/ml), and MIP-2 (1.7-fold, 134.18 vs 79.71 pg/ml), in addition to KC (1.7-fold, 177.14 vs 105.76 pg/ml) and MCP-1 (2.1-fold, 115.34 vs 55.79 pg/ml). Elevated KC and MIP-2 (murine IL-8 homologues) align with our previous finding that higher IL-8 pretreatment levels in ICI-treated cancer patients correlate with thrombosis, suggesting endothelial activation. Spearman's correlation analysis showed significant positive correlations in four cytokines between tumor and plasma of ICI-treated mice: IFN-γ (r=0.6520, p=0.0216), TNF-α (r=0.7170, p=0.0026), MIP-1β (r-0.6547, p=0.0081), and RANTES (r=0.7178, p=0.0008), indicating systemic reflection of local tumor inflammatory responses. IFN-γ correlated strongly with MCP-1 and MIP-1β in circulation (r>0.5, p>0.05). T cell depletion significantly reduced MIP-1β, RANTES, and IFN-γ levels (129 vs 60 pg/ml, p=0.0091). In vitro studies with CT26 cancer cells demonstrated that IFN-γ upregulates TF via the JAK1/2-STAT1 pathway and increases TF+EV release via IRF1-Rab27a axis, confirmed by siRNA targeting IRF1 and Rab27a.
IFN-γ released by ICI-activated T cells may upregulate TF expression and TF+EV secretion in cancer cells, and stimulate monocytes and macrophages in the TME to secrete TNF-α, MIP-1β, RANTES. Elevated circulating IFN-γ (and/or TNF-α) can activate endothelial cells to release of cytokines such as KC and MIP-2 (for neutrophils) and MCP-1 and MCP-5 (for monocytes). Thus, IFN-γ induces TF in the TME and modulates a prothrombotic state in circulation by mediating proinflammatory cytokine release. Understanding these cytokine networks and correlations will provide insight into mechanisms of IAT.
Disclosures: McCrae: Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Membership on an entity's Board of Directors or advisory committees; sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees.